Approval of the home-grown Arcus delivery technology deployed by Ardsley, N.Y.-based Acorda Therapeutics Inc. with Inbrija (levodopa inhalation powder) represents "a tremendous step forward" for the device, which vaulted "the hardest, highest hurdle" in gaining FDA clearance, CEO Ron Cohen said. "You know how many questions hung over this," he told investors during a conference call.